An Extended Follow-up Of Stroke Patients For Cognitive Impairment And Neuropsychiatric Disorders: Sydney Stroke Study
Funder
National Health and Medical Research Council
Funding Amount
$321,800.00
Summary
Vascular Dementia (VaD) is the second most common cause of dementia after Alzheimer's disease. In fact, it may be a preventable cause of dementia. Yet it has been relatively neglected by researchers until the last decade, which has seen an upsurge of interest in this disorder. There is no consensus on the criteria for dementia. The profile of early cognitive impairment due to vascular factors is still poorly understood, and the longitudinal course of VaD as defined by modern criteria has not bee ....Vascular Dementia (VaD) is the second most common cause of dementia after Alzheimer's disease. In fact, it may be a preventable cause of dementia. Yet it has been relatively neglected by researchers until the last decade, which has seen an upsurge of interest in this disorder. There is no consensus on the criteria for dementia. The profile of early cognitive impairment due to vascular factors is still poorly understood, and the longitudinal course of VaD as defined by modern criteria has not been studied. There have been few studies of the progressive changes in MRI in patients with cerebrovascular disease. The overlap of VaD and Alzheimer's disease (AD) remains a problem for taxonomists and clinicians. One approach to the study of VaD is to examine a high risk group of subjects longitudinally to determine the early features, the risk factors and progressive changes. With this in mind, we began studying a cohort of stroke patients who are at high risk of VaD, in 1997-1999, and are following them longitudinally. The follow-up is now in its third year, and three neuropsychological assessments and two MRI-MRS scans have been performed. We propose to extend the follow-up to 5 years, with repeat neuropsychiatric, neuropsychological and MRI-MRS investigations, and wherever possible to necropsy, to determine the nature of vascular pathology that underlies cognitive impairment. Our cohort of stroke patients is arguably the most comprehensively assessed such cohorts internationally, and presents an excellent opportunity for a long-term follow-up study.Read moreRead less
THE NATURAL HISTORY OF COGNITIVE IMPAIRMENT AND DEMENTIA IN A STROKE COHORT
Funder
National Health and Medical Research Council
Funding Amount
$290,747.00
Summary
In a current NHMRC-funded study, we have examined 200 stroke patients (and 100 control subjects) at 3 months after a stroke and one year later, and identified those who have impairment in memory and other cognitive functions. We have also studied these subjects in detail from a psychiatric perspective and performed brain scans on them using magentic resonance imaging. We find that many stroke patients have problems with their cognitive functioning which has a major impact on their lives. A large ....In a current NHMRC-funded study, we have examined 200 stroke patients (and 100 control subjects) at 3 months after a stroke and one year later, and identified those who have impairment in memory and other cognitive functions. We have also studied these subjects in detail from a psychiatric perspective and performed brain scans on them using magentic resonance imaging. We find that many stroke patients have problems with their cognitive functioning which has a major impact on their lives. A large number also become depressed. These consequences of stroke are not given sufficient importance by clinicians. The fact that stroke is a common problem in the elderly, and our society is aging, makes this a problem of major public health significance. In the new proposal, we plan to study these subjects up to 3 years with repeat neuropsychiatric assessments and brain scans to investigate the natural history of stroke-related cognitive impairment. We will determine whether further new cases of dementia develop in the period 1-3 years, what happens to the brain lesions picked up on brain scans, and how these deficiencies affect the patients' living status and their longevity. We will be able to determine the factors that lead to a good outcome, and suggest strategies that may be applicable to improve the functioning of these individuals.Read moreRead less
Action-reward Integration In The Amygdalocortical-striatal Network.
Funder
National Health and Medical Research Council
Funding Amount
$757,495.00
Summary
This research focuses on the neural bases of decision making, a general capacity affected by normal ageing, disorders associated with neurodegeneration, major psychiatric conditions, obesity and drug addiction. This program will contribute critical new knowledge on the brain systems through which cognitive and emotional processes are integrated to control choice and decision-making and the influence of neuropathology on this integrative process.
A Randomised Controlled Trial Of NMDA Antagonist, Memantine, For The Treatment Of Borderline Personality Disorder
Funder
National Health and Medical Research Council
Funding Amount
$993,067.00
Summary
Borderline Personality Disorder (BPD) affects 5.9% of Australians and is a poorly understood mental illness with no clear medication treatment. The key symptoms of BPD all stem from impaired cognitive processes. Our early data shows improvement of symptoms with memantine - a cognitive enhancing drug used in Alzheimer’s disease.We plan to conduct a clinical trial; giving either 20mg memantine or placebo to 150 people with BPD across 2 Victorian sites.
Dopamine-2 Receptor Antibody In Movement And Psychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$415,783.00
Summary
Autoimmune movement and psychiatric disorders are a common cause of neurological disability young adults and adolescents. We have identified a subgroup of patients whose disease is associated with an autoimmune reaction. Our study will identify the earliest immune responses against the brain in children with autoimmune movement and psychiatric disorders. Identifying these early immune responses will allow early and directed treatments to prevent disability and death in the future.
Using Genomics To Understand Psychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
The last five years have seen unprecedented discovery of DNA risk factors for psychiatric disorders. In my Fellowship I will combine analyses of genomic data with development of new statistical methodologies to contribute to my vision that application of genomics methods in psychiatry will continue to catalyze more discoveries of the causes of these complex genetic disorders.
Multivariate Whole Genome Estimation And Prediction Analysis Of Genomics Data Applied To Psychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$639,582.00
Summary
We have made major contributions to the development of statistical methods applied to data from the international Psychiatric Genomics Consortium. Major new data sets will soon become available, with immense sample sizes (100,000s) and more extensive clinical and environmental data. We will develop and apply novel statistical analyses of these data, to answer fundamental questions about the genetic basis of psychiatric disorders and the interplay of genetic and environmental risk factors.
Epigenetic Impacts Of Paternal Experience On Offspring Anxiety And Cognition: Molecular Mediators And Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$681,162.00
Summary
Stress and physical activity are two of the major lifestyle factors impacting on human health, including brain disorders. We have recently discovered that stress and exercise in male mice can impact the phenotype of offspring. We will study molecules in the sperm of these fathers, and in the brains of offspring to understand the mechanisms involved. There is evidence that lifestyle factors in men prior to conception impact on their children and this research has major public health implications.
Molecular And Cellular Characterisation Of Schizophrenia Associated Dysfunction In MicroRNA Biogenesis
Funder
National Health and Medical Research Council
Funding Amount
$496,205.00
Summary
We have identified substantial changes in the biogenesis of microRNA in schizophrenia. These small non-coding molecules derived from junk DNA, play a significant role in genetic regulation, with each one capable of silencing hundreds of target genes. This has major implications for schizophrenia, which is known to involve substantial changes in gene activity. The project will identify the molecular basis of this alteration in gene silencing, and its biological implications for schizophrenia.